rocbrutinib   Click here for help

GtoPdb Ligand ID: 12875

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor, but whose target is undisclosed.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 14
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 145.65
Molecular weight 761.91
XLogP 2.18
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=CC(=CC=C1N2CCN(C[C@]2([H])C)C3CCOCC3)NC4=NC(=CN(C)C4=O)C5=C(CO)C(=NC=C5)N6CCN7C(=CC8=C7CC(C)(C)C8)C6=O
Isomeric SMILES [H][C@]1(C)CN(CCN1C2=CC=C(NC3=NC(=CN(C)C3=O)C4=C(CO)C(=NC=C4)N5CCN6C7=C(CC(C)(C)C7)C=C6C5=O)C=C2NC(=O)C=C)C8CCOCC8
InChI InChI=1S/C42H51N9O5/c1-6-37(53)45-32-20-28(7-8-34(32)49-14-13-48(23-26(49)2)29-10-17-56-18-11-29)44-38-41(55)47(5)24-33(46-38)30-9-12-43-39(31(30)25-52)51-16-15-50-35(40(51)54)19-27-21-42(3,4)22-36(27)50/h6-9,12,19-20,24,26,29,52H,1,10-11,13-18,21-23,25H2,2-5H3,(H,44,46)(H,45,53)/t26-/m0/s1
InChI Key OYJVFTNYBWVQHA-SANMLTNESA-N